Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Second Quarter Revenues Plummet

NEW YORK, July 30 - Incyte of Palo Alto, Calif., today reported revenues of $11 million for the second quarter ending June 30, compared to revenues of $29 million for the same quarter last year.

 

The company reported research and development expenses of $30 million, compared to $38 million for the year-ago period.

 

During the quarter, the firm fired 52 employees in closing its San Diego drug discovery facility and discontinuing target validation work conducted in Palo Alto. In a statement, the company said that it saved $10 million by this consolidating of its drug discovery activities to its Delaware facility.

 

Incyte reported a net loss of $27 million, compared to $17.5 million for the year ago quarter.

 

The company reported cash and cash equivalents, and marketable securities of $361 million, compared to $430 million as of Dec. 31.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.